)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Advanced Medical Solutions Group
Advanced Medical Solutions Group (AMS) investor relations material
Advanced Medical Solutions Group H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary16 Sep, 2026
Executive summary
Group revenue rose 4% year-over-year to £115.5 million, with growth in both Surgical (+4%) and Advanced Woundcare (+5%) business units.
Adjusted EBITDA increased 8% to £26.3 million, and adjusted profit before tax rose 11% to £18.1 million.
Reported profit before tax fell sharply to £0.3 million due to £12.4 million in exceptional items related to operational synergies and acquisition costs.
The Board remains confident in delivering further progress in H2 and highlights strong long-term growth prospects.
Acquisition by H.B. Fuller is progressing, with regulatory clearances obtained and completion expected in Q4 2026.
Financial highlights
Group revenue: £115.5m (+4% year-over-year); Surgical: £91.4m (+4%); Woundcare: £24.1m (+5%).
Adjusted EBITDA: £26.3m (+8%); margin 22.7% (+0.7pp).
Adjusted profit before tax: £18.1m (+11%); margin 15.7% (+0.9pp).
Reported profit before tax: £0.3m (-96%); diluted EPS: -0.03p (vs 2.84p prior year).
Net cash inflow from operating activities: £7.4m (-51%); net debt: £60.3m (+20%).
Interim dividend: Nil (vs 0.85p prior year).
Outlook and guidance
Board expects further progress in H2 2026, citing strong competitive position and market dynamics.
Acquisition by H.B. Fuller expected to complete in Q4 2026, pending final conditions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Advanced Medical Solutions Group
- H1 2026 revenue up 4% to £115.2m; EBITDA on track; direct sales and integration drive growth.AMS
H1 2026 TU - Record revenue and EBITDA growth in 2025, with synergies and new products driving future gains.AMSH2 2025
- Revenue up 66% to £110.8m, with acquisitions and synergies fueling robust growth.AMSH1 2025
- Strong H1 2025 growth driven by core surgical products and successful integration of acquisitions.AMSTrading Update
- 10% revenue growth and strategic acquisitions drive long-term expansion despite profit impact.AMSH1 2024
- Strong revenue growth and successful acquisitions drive long-term outlook.AMSH2 2024
Next Advanced Medical Solutions Group earnings date
H2 202617 Mar, 2027
Advanced Medical Solutions Group
Next Advanced Medical Solutions Group earnings date
H2 202617 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Advanced Medical Solutions Group plc (AMS) is a leading developer and manufacturer of innovative tissue-healing technologies, serving the healthcare sector with a wide array of products aimed at improving patient outcomes. The company specializes in the design, development, manufacture, and distribution of advanced wound care products, surgical dressings, medical grade materials, and a range of adhesives and sutures for closing and sealing tissue. AMS's product portfolio includes advanced solutions like silver alginates, alginates, foams, tissue adhesives, sutures, and haemostats, catering to various needs in wound care and surgical applications.The company is headquartered in Winsford, England, and its shares are listed on the AIM market of the London Stock Exchange.